Head of Orphan Diseases Division
Venn Therapeutics is a highly innovative drug discovery incubator and immuno-oncology company developing a pipeline of novel, first-in-class agents that precisely target key mechanisms of cancer, fibrosis, and NASH, focused on integrin-mediated activation of TGF-β.Venn’s broad portfolio includes a pipeline of first-in-class antibodies targeting integrins for the treatment of cancer and fibrotic disorders. Venn leverages pioneering translational research working with world class scientific researchers at the cutting edge of the emerging field of immuno-oncology.
Remko van Leeuwen has more than 25 years of research experience under his belt, both in the industry as well as in the academic arena.
He has a medical background, and been trained as a clinical epidemiologist, and has extensive experienced in clinical infectious disease management. He has obtained a Ph.D. in clinical HIV studies.
After completing his Ph.D., he decided on a career switch and terminated his hospital-based clinical activities. Over the last 2 decades, he has various positions in drug development and clinical trial conduct. He has designed and executed numerous clinical trials and pre-clinical development programs.
He has been the team leader of large multi-national successful research projects. He carries in-depth knowledge of product development, including regulatory requirements, medical affairs, biostatistics, and data analysis. He has followed the NIABA Masterclass of Biobusiness 2009/2010. In 2011 he founded Madam Therapeutics.
Afreen Allam: Founder/CEO Ms. Allam is a graduate of North Carolina State University with a double major in microbiology and biochemistry. She subsequently graduated from Duke University’s Fuqua School of Business with her Masters of Business Administration in finance and banking. She has over 10 years of research in nanomedicine and her extensive studies on applications of carbon nanotechnology in drug delivery and bio-imaging led to the patenting of the Carbon NanoDot technology in 2013. At the age of 17 Ms.Allam had her first DNA sequence published and filed a patent at the age of 20. She has presented at numerous biomedical conferences including the Drugs & Diagnostics Conference, Biotech Research Symposium, and National Tech Connect Conference. She was a Forbes 30 under 30 finalist, Bustle Upstart awardee, Triangle Business Journal’s Rising Star Women in Business for 2019, Durham’s Women’s Achievement awardee, finalist for Mass Challenge, and NYU’s Endless Frontier Lab accelerator finalist.
Head of Pharmaceutical Research
Skilled in analytical chemistry, formulation development, chemistry, and team management.
Focusing on science and people development.
Learn from the industry’s top leading professionals. Increase your knowledge and partners under one roof
Benefits, limitations, and diversity of AI model in drug and target discovery.
Deep generative autopilot for the real world design of novel lead compound.
Complexity simplified; comprehensive data management for complex world.
Drug Targets with Genomic Support: A Genomics-based Strategic Framework for Improving Target Discovery and Accelerating Drug Development
The Sponsorship opportunity at Meridian Drug Discovery come with countless benefits.
Meetings, meet with industry's most renowned decision-makers exclusively. Dine and discuss business in a private setting; competitor friendly atmosphere.1
The exhibition, deliver yourself from the irrelevant audience, surround yourself with the right decision-makers in a business-driven environment; choose quality over quantity.3
Presentation, Devote yourself to science, feed the next generation with experience-based knowledge. Grasp the opportunity to apprise yourself and your organization.2
Networking, a new partner, the next funding, is just one introduction away. introduce yourself to the right people in the right place. Initiate a new business relationship by being in the right place at the right time.4